跳至主要内容
临床试验/EUCTR2021-000605-24-ES
EUCTR2021-000605-24-ES进行中(未招募)1 期

Double-blind Randomized Clinical Trial, Placebo-controlled to Assess the Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID: E-SPERANZA COVID PROJECT - Montelukast in Mild-moderate Respiratory Symptoms in Patients with Long-COVID

IDIAP Jordi Gol0 个研究点目标入组 284 人开始时间: 2021年7月9日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
284

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Patients aged 18 to 80 years with SARS-CoV-2 infection (positive PCR) attended in Primary Care.
  • Persistent respiratory symptoms (more than 1 and <4 months of evolution)
  • Mild-moderate dyspnea: score at baseline according to the modified Medical Research Council (mMRC) scale from 0 to 3
  • The patient must be competent to complement the follow-up evaluations.
  • The patient agrees to participate in the study and take the assigned medication during the 4 weeks.
  • Sign the informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 200
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 84

排除标准

  • Severity criteria: fever> 38ºC, or O2 saturation <93%.
  • Patients with SARS-Cov-2 pneumonia in the acute / subacute phase.
  • Patients who have required hospital admission for SARS-Cov-2.
  • Chronic Obstructive Pulmonary Disease (COPD), asthma, bronchiectasis, pulmonary fibrosis, obstructive sleep apnea syndrome (OSAS), chronic respiratory failure from any cause, home oxygen therapy.
  • Use of montelukast or zafirlukast = 30 days prior to inclusion
  • Use of gemfibrocil.
  • Hypersensitivity to montelukast, lactose intolerance or intolerance to any of the excipients of the trial treatment.
  • Active malignancy, current or recent chemotherapy treatment (<6 months).
  • Medical history of infection by the Human Immunodeficiency Virus (HIV) or any serious immunocompromised state.
  • Pregnancy or planning of being pregnant.
  • Breastfeeding mother.
  • Any other condition for which, in the opinion of the principal investigator, it is considered that the subject will not be able to perform the clinical trial procedures.

研究者

相似试验